|Other Names||Protein max, Class D basic helix-loop-helix protein 4, bHLHd4, Myc-associated factor X, MAX, BHLHD4|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP7827a was selected from the S11 region of human MAX. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Transcription regulator. Forms a sequence-specific DNA- binding protein complex with MYC or MAD which recognizes the core sequence 5'-CAC[GA]TG-3'. The MYC:MAX complex is a transcriptional activator, whereas the MAD:MAX complex is a repressor. May repress transcription via the recruitment of a chromatin remodeling complex containing H3 'Lys-9' histone methyltransferase activity.|
|Cellular Location||Nucleus. Cell projection, dendrite|
|Tissue Location||High levels found in the brain, heart and lung while lower levels are seen in the liver, kidney and skeletal muscle|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
MAX is a member of the basic helix-loop-helix leucine zipper (bHLHZ) family of transcription factors. It is able to form homodimers and heterodimers with other family members, which include Mad, Mxi1 and Myc. Myc is an oncoprotein implicated in cell proliferation, differentiation and apoptosis. The homodimers and heterodimers compete for a common DNA target site (the E box) and rearrangement among these dimer forms provides a complex system of transcriptional regulation.
Faiola,F., Biochem. J. 403 (3), 397-407 (2007)Gordan,J.D., Cancer Cell 11 (4), 335-347 (2007)Fujii,M., Mol. Cell 24 (5), 771-783 (2006)
If you have any additional inquiries please email technical services at email@example.com.